Recently, the Yangtze River Delta Biochemical Industry Conference, organized by China Biomedical Industry Chain Innovation and Transformation Alliance（CBIITA）and other institutions, was held in Hangzhou. At the conference, the 2023 China Biomedical Industry Chain Innovation Billboard was announced, in which Hansoh Pharma Pharmaceutical Group won two major prizes—“Innovative Enterprises with the Most Powerful R&D Capabilities in 2023 - Big Pharma” (second place) and “2023 New Global Independently-Developed Drug” (for pegmolesatide injection). Mr. Xu Chuanhe, the Group’s Senior Vice President, attended the conference to accept the prizes.
Saint Luolai (pegmolesatide injection), the “2023 New Global Independently-Developed Drug”, is a Class 1 innovative drug developed by Hansoh Pharma, and the only approved synthetic peptide-based erythropoietin (EPO) in the world. As a new long-acting peptide-based EPO receptor agonist, the pegmolesatide injection can be administered once every four weeks, significantly increasing patient compliance while also offering a stable standard treatment for patients with good safety. It fills the need that previously existed for monthly agents used in the treatment of renal anemia, offering hope for the long-term treatment of renal anemia. The panel believes that pegmolesatide is the world’s first drug with homologous target sequences among the innovative drugs approved by the National Medical Products Administration in 2023, characterized by its leading and innovative value.
R&D and innovation are key to Hansoh Pharma’s innovation-driven strategy. With the successful commercialization of innovative drugs such as Ameile (almonertinib mesilate), Hengmu (tenofovir amibufenamide), Haosen Xinfu (flumatinib mesylate), Fulaimei (polyethylene glycol loxenatide for injection), Mailingda (morinidazole and sodium chloride injection), Xinyue (inebilizumab injection), and Saint Luolai (pegmolesatide injection), Hansoh Pharma’s revenue in innovative drugs has increased rapidly, transforming the company into an innovative biopharmaceutical powerhouse engaged in the development and sales of innovative drugs. Hansoh Pharma boasts outstanding capabilities in the discovery of efficient micromolecules and macromolecules. The company engages in the R&D of monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), siRNA, bispecific antibodies (BsAbs), and fusion proteins (FPs). Over 30 innovative drug projects in different clinical stages are currently being carried out for more than 40 clinical trials, resulting in a rich and competitive R&D pipeline for the treatment of critical illnesses such as tumors, infections, central nervous system illnesses, metabolic disease, and autoimmune disease.
It was reported that the 2023 China Biomedical Industry Chain Innovation Billboard was launched by the CBIITA, selecting the top 10 entries in various sectors and top 3 innovations by analyzing authoritative data across multiple dimensions, validating data via experts’ grades from multiple perspectives, and voting through public procedures. The Innovation Billboard has now been released four times, and has become a benchmark in biochemical innovation and transformation. Its major prize, “New Global”, aims to select China’s innovative drugs with global original targets and new indications in order to encourage front runners in the biopharmaceutical industry. The prizes demonstrate that all sectors of society highly recognize Hansoh Pharma’s innovative capabilities.
